Resource clarifies NSF GMP, USP Verified, and FDA cGMP standards and how GMP certification drives trust, retailer ...

Scale-up involves increasing pump sizes, reactor volumes, and flow rates—but the process control logic and system ...

Sai Parenteral’s IPO has received a weak response, being subscribed only 0.42 times by Day 2. The ₹409 crore IPO includes a ...

Michelle Dennis, QC Microbiology Application Specialist with MilliporeSigma and member of the PDA Week 2026 planning ...

"The CMS pilot program could establish a federally supported cannabinoid treatment category before FDA botanical drug development standards are completed-potentially redefining how medicine enters the ...

"The CMS pilot program could establish a federally supported cannabinoid treatment category before FDA botanical drug ...

In response to evolving regulatory expectations, the industry is moving toward integrated, risk-based, and transparent ...

HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, ...

Independent oversight reinforces manufacturing, supply chain integrity, and federal readiness for a platform designed to scale across multiple ...

In line with the drug manufacturing practices followed in regulated geographies, Central Drug Standards Control Organization (CDSCO) has successfully concluded training sessions for drug inspectors on ...

Sai Parenteral IPO sees robust subscription in primary market. Sai Parenteral initial public offer (IPO) got subscribed 63 ...

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its ...